RARE CANCERBone/Soft TissueWHO 5th Edition Classification

Ewing Sarcoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

An aggressive cancer of bone and soft tissue driven by a fusion between EWSR1 and an ETS-family transcription factor, most often FLI1. It affects children and young adults, commonly involving the pelvis, chest wall and long bones, and requires both intensive systemic chemotherapy and definitive local control.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Persistent bone pain with fever in a young person can be mistaken for osteomyelitis - image before treating as infection
Who It Affects

Children, adolescents and young adults, peak 10-20 years; markedly commoner in people of European ancestry

Annual Incidence

Approximately 3 per million per year in the affected age group

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Bone pain that worsens over weeks and is often worse at night
Swelling, warmth or a tender lump over the affected area
Fever, weight loss and fatigue, which can mimic infection
A limp or reduced use of a limb
Back pain with neurological signs in spinal or pelvic tumours

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

EWSR1-FLI1 fusion, t(11;22)(q24;q12)EWSR1-ERG - variantCD99 membranous positivitySTAG2 and TP53 as adverse factors

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Interval-compressed VDC/IE chemotherapy - vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Surgical resection for local control where achievable

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Definitive radiotherapy where surgery would cause unacceptable morbidity

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

High-dose chemotherapy with stem cell rescue in selected high-risk patients

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Clinical trial enrolment, particularly at relapse

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Five-year survival is roughly 70-80% for localised disease treated on modern interval-compressed protocols, but 20-30% with metastases at diagnosis. Isolated lung metastases carry a better outlook than bone or marrow involvement. Relapse after two years is uncommon but does occur.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Targeting the EWSR1-FLI1 fusion directly, PARP inhibitor combinations, and immunotherapy including CAR-T against surface targets are the leading research directions.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Ewing Sarcoma

Browse All Oncologists

Dr. Leonard Wexler

Pediatric Oncologist

35+ yrs exp

MSKCC

New York, USA

Pediatric OncologyEwing SarcomaINT-0091 Trials
Vetted DirectoryConsult Specialist

Dr. Viulnerability Liu

Pediatric Oncologist

10+ yrs exp

NUH

Singapore, Singapore

Pediatric OncologyEwing SarcomaVIDE/VAI Chemotherapy
Vetted DirectoryConsult Specialist

Prof. Theodoros Grünewald

Oncologist

15+ yrs exp

University Hospital Essen

Essen, Germany

OncologyEwing Sarcoma BiologyEuro-E.W.I.N.G.
Vetted DirectoryConsult Specialist

Dr. Santanu Sen

Pediatric Oncologist

20+ yrs exp

Private Practice

Kolkata, India

Pediatric OncologyEwing SarcomaCooperative Protocols
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Osteosarcoma

Independent Tumor Board Review

Facing a Diagnosis of Ewing Sarcoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult